Lv3
260 积分 2025-04-14 加入
Medical management of inflammatory bowel diseases
1个月前
已完结
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
1个月前
已完结
Therapeutically harnessing extracellular vesicles
2个月前
已完结
Pediatric Developmental Drug Toxicity: Description of Juvenile Animal Studies in US FDA Prescribing Information and Assessing the Need for New Approach Methodologies
3个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
3个月前
已完结
A CDER Perspective: Landscape of New Approach Methodologies (NAMs) submitted in Drug Development Programs
3个月前
已完结
Impurity Qualification Thresholds: An IQ Survey on Emerging Industry Experience with Health Authority Feedback
4个月前
已完结
Application of new approach methodologies for nonclinical safety assessment of drug candidates
4个月前
已完结
Nutritional and Anthropometric Indices in Children Receiving Haemodiafiltration vs Conventional Haemodialysis - The HDF, Heart and Height (3H) Study
4个月前
已关闭
Nutritional and Anthropometric Indices in Children Receiving Haemodiafiltration vs Conventional Haemodialysis - The HDF, Heart and Height (3H) Study
4个月前
已关闭
皖公网安备34019202002308